The peculiar immuno-phenotypical profile associated with the drastic growth inhibition of IL-30-silenced tumor in IL-30KO mice (IL-30−/−tumors), which survived much longer than WT mice bearing IL-30 expressing tumor (64 versus 36 days, Chi-square test: p < 0.0001), prompted us to assess whether it was consistent with the histopathological features of clinical samples and patient outcome. The gene discussed is IL27; the disease is neoplasm.